Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree [Seeking Alpha]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Seeking Alpha
NVS projects 5% annual revenue growth to ~$70bn by 2030, driven by eight de-risked assets and a robust late-stage pipeline, despite looming patent cliffs. Recent M&A activity, while raising questions about pipeline confidence, is viewed as strategic to offset $12bn in expiring revenues and maintain growth momentum. I see potential for NVS shares to rise 25% by 2030, though near-term earnings softness may offer more attractive entry points as the market digests patent and pipeline risks. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » Investment Overview - Novartis Latest M&A Deal Speaks to Pipeline Pressure A few days ago (March 20th), Swiss Pharmaceuticals giant Novartis ( NVS announced it would pay $2bn up front (the deal may rise to $3bn if milestones are met) to acquire Pikavation Therapeutics, a wholly owned subsidiary of Synnovation, a privately owned Biotech headquartered in Delaware. The clue is in the nam
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis (NVS) had its price target raised by Morgan Stanley from $143.00 to $170.00. They now have an "overweight" rating on the stock.MarketBeat
- Is iShares International Equity Factor ETF (INTF) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 [Yahoo! Finance]Yahoo! Finance
- Novartis (NVS) was upgraded by Sanford C. Bernstein to "hold".MarketBeat
- Novartis Strikes $3B Oncology Deal for Breast Cancer Asset [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form FWP
- 2/12/26 - Form 144
- NVS's page on the SEC website